Entyvio Dosage Specifics: Potency, Forms, Administration Methods, and Further Details
Entyvio: A New Option for Managing Crohn's Disease and Ulcerative Colitis
Entyvio, a brand-name prescription drug, offers a promising solution for adults living with active Crohn's disease (CD) and ulcerative colitis (UC). This biologic medication comes in two forms: intravenous (IV) infusion and subcutaneous (SC) injection.
During IV infusions, patients are closely monitored for any side effects related to the infusion. In clinical trials, the maintenance dose of Entyvio IV infusion was found to be safe and effective every 8 weeks for treating CD and UC.
The recommended dosage schedule for Entyvio in adults with CD and UC is as follows:
Intravenous (IV) infusion: - Initial dosing: 300 mg IV over 30 minutes at Week 0, Week 2, and Week 6. - Maintenance dosing: 300 mg IV infusion every 8 weeks thereafter.
After the first two IV doses at Week 0 and Week 2, patients may switch to SC injections starting at Week 6. The maintenance dosing with SC injection is 108 mg subcutaneously once every 2 weeks. The first SC injection replaces the scheduled IV infusion at Week 6, then continues every 2 weeks. Therapy should be discontinued if there is no therapeutic benefit by Week 14.
The Entyvio single-dose prefilled syringe and injection pen for SC injection comes in one strength: 108 mg/0.68 milliliters (mL). Patients should store the Entyvio syringe or pen in the refrigerator between 36°F to 46°F (2°C to 8°C) and let it come to room temperature before injecting.
It's important to note that Entyvio is not approved for use in children as it has not been studied in this age group. Additionally, Entyvio injections should be administered in the abdomen (2 inches away from the navel), thigh, or upper arm, avoiding tender, red, discolored, or hardened areas of the skin, moles, scars, or bruises.
If a patient misses an Entyvio infusion appointment, they should reschedule it as soon as possible. If they miss an Entyvio subcutaneous injection at home, they should inject the next dose as soon as possible and then inject it every 2 weeks afterward.
Entyvio can be self-administered at home using a single-dose prefilled syringe or single-dose prefilled injection pen after the initial infusions. IV dosing is 300 mg every 8 weeks after induction, while SC dosing is 108 mg every 2 weeks. SC injection is used as a maintenance option after initial IV induction doses. IV infusions take about 30 minutes to administer in a clinical setting; SC injections can be self-administered after training.
Entyvio is meant to be used as a long-term treatment, but it's crucial to discuss any concerns or questions about the medication with a healthcare professional.
[1] Reference: Entyvio Prescribing Information. Takeda Pharmaceuticals U.S.A., Inc. [Accessed 2022-03-21]. [3] Reference: Entyvio Patient Information. Takeda Pharmaceuticals U.S.A., Inc. [Accessed 2022-03-21].
- AbbVie, the manufacturer of Entyvio, has developed a new treatment option for adults managing active Crohn's disease and ulcerative colitis.
- For initial treatment, Entyvio is administered as an intravenous infusion in three doses over a six-week period, followed by a maintenance dose every eight weeks.
- After the initial two IV doses, some patients may switch to subcutaneous injections starting at Week 6, which are given every two weeks.
- A person seeking treatment for anthrax or heart-related conditions should not consider Entyvio, as it is only approved for ulcerative colitis and Crohn's disease.
- Science and medical-conditions like colitis and CDI have found potential relief through therapies and treatments like Entyvio, contributing to the health and wellness of countless individuals.
- Entyvio is not recommended for use in children as its safety and efficacy have not been established in that age group.
- Switchers, or those considering a change in treatment, may find Entyvio subcutaneous injections an appealing option, offering the same effectiveness as the initial IV infusions with a more convenient self-administration schedule.
